The oncogenic mechanism of activating BRAF mutations, such as BRAFV600E, is known to promote MEK-ERK activation; however, the biological role of kinase-inactive BRAF mutations, which are more common in lung adenocarcinoma than the activating BRAFV600E mutation [111,112], is not known. This evidence concerns the gene BRAF and lung adenocarcinoma.